Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway.

Ford NF.

J Clin Pharmacol. 2016 Dec;56(12):1474-1483. doi: 10.1002/jcph.769. Epub 2016 Jun 22. Review.

PMID:
27196064
2.

Clopidogrel and Genotyping.

Ford NF.

J Invasive Cardiol. 2015 Aug;27(8):E173-4. Review. No abstract available.

3.

Clopidogrel: what is a cardiologist to do?

Ford NF.

J Clin Pharmacol. 2014 Aug;54(8):881-3. doi: 10.1002/jcph.330. No abstract available.

PMID:
24824921
4.

Clopidogrel, CYP2C19, and a Black Box.

Ford NF, Taubert D.

J Clin Pharmacol. 2013 Mar;53(3):241-8. doi: 10.1002/jcph.17. Epub 2013 Feb 4.

PMID:
23381692
5.

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.

Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D.

BMJ. 2011 Aug 4;343:d4588. doi: 10.1136/bmj.d4588. Review.

6.

Clopidogrel resistance: pharmacokinetic or pharmacogenetic?

Ford NF.

J Clin Pharmacol. 2009 May;49(5):506-12. doi: 10.1177/0091270009332433. Epub 2009 Feb 26. Review.

PMID:
19246723
7.

Vasodilator effects of the endothelin ET receptor selective antagonist BMS-193884 in healthy men.

Dhaun N, Strachan FE, Newby DE, Johnston NR, Ford NF, Hammett JL, Palmisano M, Webb DJ.

Br J Clin Pharmacol. 2005 Dec;60(6):611-22.

8.

Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.

Hennekens CH, Sacks FM, Tonkin A, Jukema JW, Byington RP, Pitt B, Berry DA, Berry SM, Ford NF, Walker AJ, Natarajan K, Sheng-Lin C, Fiedorek FT, Belder R.

Arch Intern Med. 2004 Jan 12;164(1):40-4.

PMID:
14718320
9.

The pharmacokinetics of irbesartan in hypertensive children and adolescents.

Sakarcan A, Tenney F, Wilson JT, Stewart JJ, Adcock KG, Wells TG, Vachharajani NN, Hadjilambris OW, Slugg P, Ford NF, Marino MR.

J Clin Pharmacol. 2001 Jul;41(7):742-9.

PMID:
11452706
10.

Pharmacodynamics and Pharmacokinetics of Irbesartan in Patients With Mild to Moderate Hypertension.

Marino MR, Langenbacher KM, Ford NF, Raymond RH, Manning J, Vesterqvist O, Shamblen EC, Lasseter KC.

J Cardiovasc Pharmacol Ther. 1999 Apr;4(2):67-75.

PMID:
10684525
11.

Effect of Nifedipine on the Steady-State Pharmacokinetics and Pharmacodynamics of Irbesartan in Healthy Subjects.

Marino MR, Hammett JL, Ferreira I I, Ford NF, Uderman HD.

J Cardiovasc Pharmacol Ther. 1998 Apr;3(2):111-118.

PMID:
10684488
12.
13.

Clinically significant cytochrome P-450 drug interactions--a comment.

Ford NF, Sonnichsen DS.

Pharmacotherapy. 1998 Jul-Aug;18(4):890-1; discussion 892-3. No abstract available.

PMID:
9692671
14.

Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis.

Marino MR, Langenbacher KM, Raymond RH, Ford NF, Lasseter KC.

J Clin Pharmacol. 1998 Apr;38(4):347-56.

PMID:
9590462
15.

Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects.

Marino MR, Langenbacher K, Ford NF, Uderman HD.

J Clin Pharmacol. 1998 Mar;38(3):246-55.

PMID:
9549663
16.

Monitoring of acute migraine attacks: placebo response and safety data.

Jhee SS, Salazar DE, Ford NF, Fulmor IE, Sramek JJ, Cutler NR.

Headache. 1998 Jan;38(1):35-8.

PMID:
9505001
17.

The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis.

Sica DA, Marino MR, Hammett JL, Ferreira I, Gehr TW, Ford NF.

Clin Pharmacol Ther. 1997 Dec;62(6):610-8.

PMID:
9433389
18.

Measurement of 2,4-toluenediamine in urine and serum samples from women with Même or Replicon breast implants.

Hester TR Jr, Ford NF, Gale PJ, Hammett JL, Raymond R, Turnbull D, Frankos VH, Cohen MB.

Plast Reconstr Surg. 1997 Oct;100(5):1291-8.

PMID:
9326795
19.

The pharmacokinetics of pravastatin in patients on chronic hemodialysis.

Gehr TW, Sica DA, Slugg PH, Hammett JL, Raymond R, Ford NF.

Eur J Clin Pharmacol. 1997;53(2):117-21.

PMID:
9403282
20.

Evaluation of cerebral pharmacokinetics of the novel antidepressant drug, BMS-181101, by positron emission tomography.

Christian BT, Livni E, Babich JW, Alpert NM, Dischino DD, Ruediger E, Salazar DE, Ford NF, Fischman AJ.

J Pharmacol Exp Ther. 1996 Oct;279(1):325-31.

PMID:
8859010
21.

Invasive pharmacodynamics of fosinopril in patients with congestive heart failure.

Ford NF, Natarajan C, Fulmor IE, Smith RA, Hui KK.

J Clin Pharmacol. 1995 Aug;35(8):785-93. Erratum in: J Clin Pharmacol 1996 Nov;36(11):1079.

PMID:
8522635
22.

Single-dose and steady-state pharmacokinetics of fosinopril and fosinoprilat in patients with hepatic impairment.

Ford NF, Lasseter KC, Van Harken DR, Hammett JL, Raymond R, Manning J.

J Clin Pharmacol. 1995 Feb;35(2):145-50.

PMID:
7751424
23.

Fosinopril monotherapy: relationship between blood pressure reduction and time of administration.

Ford NF, Fulmor IE, Nichola PS, Alpin PG, Herron JM.

Clin Cardiol. 1993 Apr;16(4):324-30.

24.
25.

Imidazo[1,5-a]pyridines: a new class of thromboxane A2 synthetase inhibitors.

Ford NF, Browne LJ, Campbell T, Gemenden C, Goldstein R, Gude C, Wasley JW.

J Med Chem. 1985 Feb;28(2):164-70.

PMID:
3918169

Supplemental Content

Support Center